Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Harrold, Emily
Keane, Fergus
Sinopoli, Jenna Cohen
Diaz, Luis A.
Cercek, Andrea
Yaeger, Rona
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, GME Off, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
190
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [21] Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study
    Kopetz, S.
    Murphy, D. A.
    Pu, J.
    Yaeger, R.
    Ciardiello, F.
    Desai, J.
    Van Cutsem, E.
    Wasan, H. S.
    Yoshino, T.
    Alkuzweny, B.
    Xie, T.
    Zhang, X.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S681 - S682
  • [22] Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
    Yaeger, Rona
    Chatila, Walid K.
    Lipsyc, Marla D.
    Hechtman, Jaclyn F.
    Cercek, Andrea
    Sanchez-Vega, Francisco
    Jayakumaran, Gowtham
    Middha, Sumit
    Zehir, Ahmet
    Donoghue, Mark T. A.
    You, Daoqi
    Viale, Agnes
    Kemeny, Nancy
    Segal, Neil H.
    Stadler, Zsofia K.
    Varghese, Anna M.
    Kundra, Ritika
    Gao, Jianjiong
    Syed, Aijazuddin
    Hyman, David M.
    Vakiani, Efsevia
    Rosen, Neal
    Taylor, Barry S.
    Ladanyi, Marc
    Berger, Michael F.
    Solit, David B.
    Shia, Jinru
    Saltz, Leonard
    Schultz, Nikolaus
    CANCER CELL, 2018, 33 (01) : 125 - +
  • [23] A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)
    Siena, S.
    Sartore-Bianchi, A.
    Karthaus, M.
    Smith, D.
    Garcia-Carbonero, R.
    Van Cutsem, E.
    Guan, X.
    Boedigheimer, M.
    Sidhu, R.
    Jung, A. S.
    Oliner, K. S.
    Tabernero, J.
    Bardelli, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S394 - S395
  • [24] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Leto, Simonetta M.
    Trusolino, Livio
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 709 - 722
  • [25] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Simonetta M. Leto
    Livio Trusolino
    Journal of Molecular Medicine, 2014, 92 : 709 - 722
  • [26] Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC).
    Lakdawalla, D.
    Penrod, J.
    Maclean, R.
    Humphrey, J. S.
    Seabury, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [27] Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM)
    Bayle, Arnaud
    Belcaid, Laila
    Cousin, Sophie
    Palmieri, Lola-Jade
    Spalato, Mariella
    Aldea, Mihaela
    Vasseur, Damien
    Alame, Melissa
    Soubeyran, Isabelle
    Nicotra, Claudio
    Ngocamus, Maud
    Ponce, Santiago
    Loriot, Yohann
    Besse, Benjamin
    Lacroix, Ludovic
    Rouleau, Etienne
    Oxnard, Geoffrey R.
    Barlesi, Fabrice
    Andre, Fabrice
    Italiano, Antoine
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Use of palliative chemotherapy and targeted agents in elderly patients with metastatic colorectal cancer (mCRC).
    Chan, Matthew
    Renouf, Daniel John
    Speers, Caroline
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] USE OF PALLIATIVE CHEMOTHERAPY AND TARGETED AGENTS IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)
    Cheung, W. Y.
    Renouf, D.
    Lim, H.
    Kennecke, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 215 - 215
  • [30] Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence
    Rico, Gonzalo Tapia
    Townsend, Amanda R.
    Broadbridge, Vy
    Price, Timothy J.
    DRUGS & AGING, 2017, 34 (03) : 173 - 189
12345